AT1 Receptor Antagonists: Pharmacological Treatment of Hypertension in Brazil

Vanessa Pepeliascov¹, Kleber de Magalhães Galvão¹, Dones Cláudio Janz Jr², Helen Dutra Leite³ and Felipe de Lara Janz^3,

¹Bandeirante University, Sao Paulo, Brazil

²Ponta Grossa StateUniversity, Ponta Grossa Brazil

³Universityof São Paulo, Sao Paulo, Brazil

Cite this paper:
Vanessa Pepeliascov, Kleber de Magalhães Galvão, Dones Cláudio Janz Jr, Helen Dutra Leite and Felipe de Lara Janz. AT1 Receptor Antagonists: Pharmacological Treatment of Hypertension in Brazil. Biomedical Science and Engineering. 2015; 3(2):41-45. doi: 10.12691/bse-3-2-3

Abstract

High blood pressure (HBP) is a multifactorial disease that affects millions of people around the world and contributes to a large number of deaths due to acute myocardial infarction, stroke and chronic kidney disease. Its etiology remains inconclusive, but it is known that it arises of central and peripheral catecholaminergic dysfunction. Thus, cellular mechanisms are still under investigation. Its pathophysiology is characterized by an increase in systolic and diastolic blood pressure levels. The national and international guidelines for hypertension indicate that effective pharmacotherapy provides a control in blood pressure values and mortality⁄ morbidityreduction. Classes of antihypertensive drugs available for clinical use are diuretics, beta-blockers, alpha-blockers, sympatholytic, calcium channel antagonists, angiotensin converting enzyme inhibitors and angiotensin receptor antagonists of angiotensin II (ARBs). ARBs (i.e.: candesartan, irbesartan, losartan, olmesartan, telmisartan and valsartan)represent current and often used drug class in Brazil.They have different molecular configurations with independent action mechanismsin angiotensin II AT1 receptor. The objective of this paper is to discuss the pathophysiology and pharmacotherapy of hypertension, emphasizing the antagonists of angiotensin II used in Brazil, since they constitute a class of antihypertensive drugs that has fewer side effects and greater therapeutic efficacy.

Keywords:
high blood pressure pharmacotherapy angiotensin II antagonists

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Cesaretti, Mario Luis Riberio; Ginoza, Milton; Kohimann Junior, Osvaldo. Neural mechanisms: sympathetic nervous system. In: Ribeiro, Artur Beltrame; Plavnik, Frida Liane. Update on clinical hypertension, diagnostic and therapeutic: Pathophysiology of hypertension. London: Atheneu, 2008. Chapter 9, p. 79-85.
[2]	Krieger, Eduardo Moacyr; Irigoyen, Maria Claudia; Krieger, José Eduardo. Pathophysiology of hypertension. Journal of Cardiolologia Society of the State of São Paulo, São Paulo, P.01-7, 1999.
[3]	Ribeiro, José Márcio; Florencio Leonardo P.Pharmacological blockade of the renin-angiotensin-aldosterone system: converting enzyme inhibition and AT1 receptor antagonism. Brazilian Journal of Hypertension, Sao Paulo, n., P.293-302, 2000.
[4]	PR Vade Mecum. Vade Mecum medications. RGR 17 publications ed. São Paulo, 2011.
[5]	Rang, H.P; Dale, M.M, Pharmacology, 3rd ed. Publisher Koogan Guanabara, Rio de Janeiro, 1997.
[6]	Guyton, AC, HallL, JE Treaty of Medical Physiology 10. Ed. Rio de Janeiro Guanabara Koogan 2002.
[7]	Cipullo, José Paulo et al. Prevalence and Risk Factors for Hypertension in a Brazilian Population Urbana. Brazilian Archives of Cardiology, Sao Paulo, P.520-526, 2010.
[8]	Franklin, Stanley S. et al. Cardiovascular Morbidity and Mortality in Hypertensive Patients with Lower Risk Higher Versus LIFE Substudy. American Heart Association, Dallas, p.492-499, 2005.
[9]	Gomes, Marco Antonio Mota et al. Treatment of Hypertension with olmesartan medoxomil in scheduling. Brazilian Archives of Cardiology, Sao Paulo, p.185-193, 2008.
[10]	Kreutz, R. Olmesartan / amlodipine: A review of its use in the management of hypertension. Vascular Health andRisk Management, Princeton, p. 183-192. 2011.
[11]	Lopes, Heno Ferreira; GIL, Juliana Dos Santos; Consolim-Colombo, Fernanda Marciano. Activation of the adrenergic system, renin-angiotensin-aldosterone, endothelin and adrenomedullin in hypertension. Journal of the Society of Cardiology of the State of São Paulo, São Paulo, v. 18, no. 2, p.102-107, 2008.
[12]	Mion Jr, Decius et al. The importance of antihypertensive medication treatment adherence. Brazilian Journal of Hypertension, Rio de Janeiro, p.55-58, 2006.
[13]	Neves, Francis ofAssisi; Campos, Alessandra Menezes. Renin-angiotensin-aldosterone In: Ribeiro, Arthur Beltrame; Plavnik, Frida Liane Update on clinical hypertension, diagnosis and treatment. London: Atheneu, 2008.
[14]	Oigman, Wille; Fritsche, Mario Toros. Drugs that intervene in the renin-angiotensin system. Brazilian Journal of Hypertension, Rio de Janeiro, v.5, p.84-90, 1998.
[15]	Oparil, Suzanne et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of primary hypertension. The jornaul of Clinical Hypertension, vol. 3, no. 5, p. 202-282, 2001.
[16]	Tamargo, Juan et al. Pharmacological characteristics of ARB them. Son all iguales? Spanish Journal of Cardiology, vol. 6, p 10-24, 2006.
[17]	Trapp, Silvia Manduca, VailatiI, Maria do Carmo Fernandes, Matsubara, Beatriz Bojikian, Schwartz, Denise Saretta. Effects of angiotensin II in the cardiovascular system. Archives of Veterinary Science, North America, 14, jun. 2009.
[18]	Verdecchia, Paolo et al. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vascular Health and Risk Management, Princeton, n., P.939-949, November 2008.
[19]	Rigatto, Katya Vianna, Bohlke, Maristela, Irigoyen, Maria Claudia. Renin angiotensin system: from physiology to therapy. Magazine Society of Cardiology of Rio Grande do Sul. 2004.
[20]	Salgado, Wilson. Control of blood pressure to prevent cardiovascular disease. In: Santos, Raul D. Manual of prevention of cardiovascular diseases. London: Atha, 2008.
[21]	Povoa, Rui; Bombig, Maria Teresa Nogueira. Hypertension secondarily renal and endocrine origin: diagnosis and treatment. Journal of Cardiolologia Society of the State of São Paulo, São Paulo, n., P.122-134, 2008.
[22]	Consolim-Colombo, Fernanda M; Krieger, Eduardo Moacyr. Sympathetic nervous system and hypertension. Brazilian Hypertension magazine, Rio de Janeiro, v 11, p. 275-278, 2004.
[23]	Correa, Thiago Domingos et al. Hypertension: an update on the epidemiology, diagnosis and treatment. Medical files Abc, Sao Paulo, n. 5, P.90-101, 2006.
[24]	Brazilian Guidelines on Hypertension, Brazilian Archives of Cardiology, vol. 95, 2010.
[25]	BRASIL. Ministério da Saúde. Cadernos de Atenção Básica: Hipertensão Arterial Sistêmica. n. 15. Brasília, 2006.Link: http://bvsms.saude.gov.br/bvs/publicacoes/caderno_atencao_basica15.pdf.